Thieme E-Books & E-Journals -
Thromb Haemost 2023; 123(10): 955-965
DOI: 10.1055/s-0043-1769788
New Technologies, Diagnostic Tools and Drugs

Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A

Authors

  • Debora Bertaggia Calderara*

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
  • Rita Marchi Cappelletti*

    2   Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
  • Ana Patricia Batista Mesquita Sauvage

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
  • Stéphane Durual

    3   Biomaterials Laboratory, University Clinics of Dental Medicine, University of Geneva, Switzerland
  • Francisco J. Gomez

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
  • Maxime G. Zermatten

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
  • Alessandro Aliotta

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
  • Alessandro Casini**

    4   Department of Medicine, University of Geneva, Geneva, Switzerland
    5   Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
  • Lorenzo Alberio**

    1   Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland